Correlation of prostate-specific antigen before prostate cancer detection and clinicopathologic features: Evaluation of mass screening populations

Urology

Volumn 55, Issue 5, 2000, Pages 705-709

  Ito, Kazuto ^a   Kubota, Yutaka ^a   Suzuki, Kazuhiro ^a   Shimizu, Nobuaki ^a   Fukabori, Yoshitatsu ^a   Kurokawa, Kohei ^a   Imai, Kyoichi ^a   Yamanaka, Hidetoshi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD; HUMAN; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE TUMOR; TIME;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0034183156     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00568-3     Document Type: Article

References (15)

1. Carter HB, Pearson JD, Metter JE, et al: Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2220, 1992.
2. Chybowski F, Larson-Keller J, Bergstralh E, et al: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate-specific antigen is superior to all other clinical parameters. J Urol 145: 313-318, 1991.
3. Oesterling J, Martin S, Bergstralh E, et al: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269: 57-60, 1993.
4. Vijayakumar V, Vijayakumar S, Quadri S, et al: Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer? Am J Clin Oncol 17: 432-436, 1994.
5. Levran Z, Gonzalez JA, Diokno AC, et al: Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostate cancer? Br J Urol 75: 778-781, 1995.
6. Machida T, Miki M, Ohishi Y, et al: Clinical value of serum prostatic acid phosphatase determined by radioimmunoassay. Jpn J Urol 72: 416-422, 1981.
7. Manseck A, Pilarsky C, Froschermaier S, et al: Diagnostic significance of prostate-specific antigen velocity at intermediate PSA serum levels in relation to the standard deviation of different test systems. Urol Int 60: 25-27, 1998.
8. Partin DM, and Muir CS: Cancer incidence in five continents. Comparability and quality of data. IARC Sei Publ 120: 45-173, 1992.
9. Mettlin C, Lee F, Drago J, et al: The American Cancer Society national prostate cancer detection project: findings on the detection of early prostate cancer in 2425 men. Cancer 67: 2949-2958, 1991.
10. Labrie F, Dupont A, Suburu R, et al: Serum prostate specific antigen as prescreening test for prostate cancer. J Urol 147: 846-852, 1992.
11. Catalona WJ, Smith DS, Ratlill TL, et al: Detection of organ-confined prostate cancer is increased through prostate-specific antigen based screening. JAMA 270: 948-954, 1993.
12. Brawer MK, Chetner MP, Beatie J, et al: Screening for prostate carcinoma with prostate specific antigen. J Urol 147: 841-845, 1992.
13. Ito K, Kubota Y, Banzai R, et al: The present status, problems, and luture of mass screening for prostate cancer in Gunma prefecture. The report of Mass Screening for Prostate Cancer Study meeting in 1998. Kitakanto Med J 49: 81-88, 1999.
14. Cleave ME, Coupland D, Drachenberg D, et al: Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 47: 708-712, 1996.
15. Ito K, Ichinose Y, Yamanaka H, et al: Clinicopathological features of prostate cancer detected by transrectal ultrasonography-guided systematic six-sextant biopsy. Int J Urol 4: 474-479, 1997.